AU2002249467A1 - Screening method - Google Patents

Screening method

Info

Publication number
AU2002249467A1
AU2002249467A1 AU2002249467A AU2002249467A AU2002249467A1 AU 2002249467 A1 AU2002249467 A1 AU 2002249467A1 AU 2002249467 A AU2002249467 A AU 2002249467A AU 2002249467 A AU2002249467 A AU 2002249467A AU 2002249467 A1 AU2002249467 A1 AU 2002249467A1
Authority
AU
Australia
Prior art keywords
screening method
screening
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2002249467A
Inventor
Peter Andrews
Jon Draper
James Walsh
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Axordia Ltd
Original Assignee
Axordia Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Axordia Ltd filed Critical Axordia Ltd
Publication of AU2002249467A1 publication Critical patent/AU2002249467A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5014—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing toxicity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6897—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids involving reporter genes operably linked to promoters
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/10—Screening for compounds of potential therapeutic value involving cells
AU2002249467A 2001-05-04 2002-04-29 Screening method Abandoned AU2002249467A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB0111004.8 2001-05-04
GBGB0111004.8A GB0111004D0 (en) 2001-05-04 2001-05-04 Screening method
PCT/GB2002/001946 WO2002090992A2 (en) 2001-05-04 2002-04-29 Screening method

Publications (1)

Publication Number Publication Date
AU2002249467A1 true AU2002249467A1 (en) 2002-11-18

Family

ID=9914069

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2002249467A Abandoned AU2002249467A1 (en) 2001-05-04 2002-04-29 Screening method

Country Status (3)

Country Link
AU (1) AU2002249467A1 (en)
GB (1) GB0111004D0 (en)
WO (1) WO2002090992A2 (en)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1429812A4 (en) * 2001-07-17 2006-04-26 Massachusetts Inst Technology Unique properties of stem cells
US7193069B2 (en) 2002-03-22 2007-03-20 Research Association For Biotechnology Full-length cDNA
DE10319478A1 (en) * 2003-04-30 2004-11-18 Universität Zu Köln siRNA selection process
EP1758926A4 (en) 2004-05-21 2008-04-16 Univ California Methods for treating and diagnosing cancer with wnt inhibitory factor-1 (wif-1)
CA2567810A1 (en) 2004-05-27 2005-12-08 Acceleron Pharma Inc. Cerberus/coco derivatives and uses thereof
US9045553B2 (en) 2004-05-27 2015-06-02 Acceleron Pharma, Inc. Cerberus/Coco derivatives and uses thereof
US7655465B2 (en) 2004-06-07 2010-02-02 Massachusetts Institute Of Technology Methods for ex vivo propagation of somatic hair follicle stem cells
AU2006261850B2 (en) * 2005-06-22 2011-06-16 Cxr Biosciences Limited Reporter hepatocytes and other cells for drug screening and toxicity testing
US7824912B2 (en) 2005-06-23 2010-11-02 Massachusetts Institute Of Technology Methods for ex vivo propagation of adult hepatic stem cells
EP2099471A2 (en) 2006-12-08 2009-09-16 Acceleron Pharma, Inc. Uses of cerberus, coco and derivatives thereof
EP3027751A4 (en) * 2013-08-02 2017-02-15 University Of Georgia Research Foundation, Inc. Cryptosporidium transfection methods and transfected cryptosporidium cells

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU734704B2 (en) * 1996-05-30 2001-06-21 Cellomics, Inc. Miniaturized cell array methods and apparatus for cell-based screening
AU730100B2 (en) * 1997-02-27 2001-02-22 Cellomics, Inc. A system for cell-based screening
EP1196774A2 (en) * 1999-07-27 2002-04-17 Cellomics, Inc. Miniaturized cell array methods and apparatus for cell-based screening
EP1212355A2 (en) * 1999-09-13 2002-06-12 American Home Products Corporation Pharmaceutical compositions and methods of using secreted frizzled related protein

Also Published As

Publication number Publication date
WO2002090992A2 (en) 2002-11-14
GB0111004D0 (en) 2001-06-27
WO2002090992A3 (en) 2003-12-04

Similar Documents

Publication Publication Date Title
AU2002300432A1 (en) Screening Arrangement
EP1378749A4 (en) Screening method
EP1469316A2 (en) Screening method
AU2002339707A1 (en) Genetic screening methods
AU2002249467A1 (en) Screening method
AU2003277663A1 (en) Screening method
AU2003242340A1 (en) Novel screening method
AU2002341150A1 (en) Method
AU2002247215A1 (en) Method for screening compounds
AU2003227268A1 (en) Novel screening method
AU2002354247A1 (en) Screening method
AU2002348807A1 (en) Screening method which uses BNPI and DNPI
AUPR633101A0 (en) Method
AU2003242342A1 (en) Novel screening method
AU2000224577A1 (en) Screening method
AU2003217008A1 (en) Screening method
AU2002308561A1 (en) Selection method
AU2002330455A1 (en) Screening method
AU2002344589A1 (en) Screening method
AU2002230174A1 (en) Screening method
AU2002308962A1 (en) Screening method
AU2002253561A1 (en) Screening method
AU2002248009A1 (en) Screening method
AU2001288116A1 (en) Screening method
AU2002220868A1 (en) Screening method

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase